Cryptococcal meningitis in an HIV-negative patient: clinical case report
DOI:
https://doi.org/10.29076/issn.2602-8360vol8iss15.2024pp122-126pKeywords:
cryptococcal, cryptococcosis, meningitisAbstract
Cryptococcal meningitis is a mycosis caused by Cryptococcus neoformans and Gattii, which is transmitted by air and affects the lungs and central nervous system. This disease is a common cause of meningitis in patients with HIV/AIDS; however, in recent years there has been an increase of cases in immunocompetent patients, for this reason, the following case report is made. The objective of this report is to present the case of a patient with cryptococcal meningitis in the absence of HIV infection by reviewing the clinical history. The following is the case of a 67-year-old male with a history of arterial hypertension, under treatment with losartan and amlodipine, who came to the emergency room with a clinical picture of asthenia, algic with severe headache 7/10 VAS scale, the clinical picture evolves with decreased strength in the lower limbs and severe headache 10/10. The need for further investigation of the immunopathological mechanisms of cryptococcal infection in seronegative individuals is emphasized, as understanding the immune responses could improve diagnosis and treatment. In cryptococcal meningitis, elevated intracranial pressure influences prognosis in 50% of cases. Limited diagnostic resources and time hinder accurate identification of the cause and effective treatment in seronegative patients.
Downloads
References
1. Rathore SS, Sathiyamoorthy J, Lalitha C, Ramakrishnan J. A holistic review on Cryptococcus neoformans. Microbial Pathogenesis. 2022;166:105521. doi: 10.1016/j.micpath.2022.105521
2. Wykowski J, Galagan SR, Govere S, Wallis CL, Moosa MY, Celum C, et al. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm3. BMC Infect Dis. 2020;20(1):61. doi: 10.1186/s12879-020-4798-1
3. New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV. Available from: https://www.who.int/news/item/20-04-2022-rapid-advice-new-guidelines-for-simpler-safer-treatment-for-cryptococcal-disease-in-plhiv
4. Ramírez-Ramos C, Galindo J, Correa S, Giraldo-Bahamon G, Rivera J, Solano J, et al. Meningitis criptocóccica en pacientes sin infección por VIH: presentación de dos casos y revisión de la literatura. Rev Chilena Infecto. 2018;35(6):716–21.
5. Hurtado García S, Quintero-Cusgüen P. Criptococosis meníngea. Acta Neurol Colomb. 2021;37(1 Supl 1):90–100. doi: 10.4067/S0716-10182018000600716
6. Woo YH, Martinez LR. Cryptococcus neoformans-astrocyte interactions: effect on fungal blood brain barrier disruption, brain invasion, and meningitis progression. Crit Rev Microbiol. 2021;47(2):206–23. doi: 10.1080/1040841X.2020.1869178
7. Paccoud O, Desnos-Ollivier M, Cassaing S, Boukris-Sitbon K, Alanio A, Bellanger AP, et al. Cryptococcus neoformans Infections Differ Among Human Immunodeficiency Virus (HIV)-Seropositive and HIV-Seronegative Individuals: Results From a Nationwide Surveillance Program in France. Open Forum Infect Dis. 2024;11(2):ofad658. doi: 10.1093/ofid/ofad658
8. Chen J, Shao J, Dai M, Fang W, Yang YL. Adaptive immunology of Cryptococcus neoformans infections-an update. Front Immunol. 2023;14:1174967. doi: 10.3389/fimmu.2023.1174967
Downloads
Published
Issue
Section
License
Copyright (c) 2024 FACSALUD-UNEMI
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los artículos de la Revista FACSalud UNEMI son difundidos bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Los autores mantienen los derechos de autor, y, por lo tanto, son libres de compartir, copiar, distribuir, ejecutar y comunicar públicamente la obra bajo las condiciones siguientes: Reconocer los créditos de la obra especificada por el autor e indicar si se realizaron cambios (puede hacerlo de cualquier forma razonable, pero no de una manera que sugiera que el autor respalda el uso que hace de su obra. No utilizar la obra para fines comerciales. En caso de remezcla, transformación o desarrollo, no puede distribuirse el material modificado.